BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30776159)

  • 1. In vitro combination between antifungals and diphenyl diselenide against Cryptococcus species.
    Rossato L; Loreto ES; Venturini TP; de Azevedo MI; Al-Hatmi AMS; Santurio JM; Alves SH
    Mycoses; 2019 Jun; 62(6):508-512. PubMed ID: 30776159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro anti-Cryptococcus activity of diphenyl diselenide alone and in combination with amphotericin B and fluconazole.
    Benelli JL; Poester VR; Munhoz LS; Klafke GB; Stevens DA; Xavier MO
    Braz J Microbiol; 2021 Dec; 52(4):1719-1723. PubMed ID: 34195915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal activities of diphenyl diselenide alone and in combination with fluconazole or amphotericin B against Candida glabrata.
    Denardi LB; Mario DA; de Loreto ES; Nogueira CW; Santurio JM; Alves SH
    Mycopathologia; 2013 Aug; 176(1-2):165-9. PubMed ID: 23793863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
    Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal activities of diphenyl diselenide and ebselen alone and in combination with antifungal agents against Fusarium spp.
    Venturini TP; Chassot F; Loreto ÉS; Keller JT; Azevedo MI; Zeni G; Santurio JM; Alves SH
    Med Mycol; 2016 Jul; 54(5):550-5. PubMed ID: 26773133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
    Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
    Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
    Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
    Dannaoui E; Abdul M; Arpin M; Michel-Nguyen A; Piens MA; Favel A; Lortholary O; Dromer F;
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2464-70. PubMed ID: 16801427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
    Mahabeer Y; Chang CC; Naidu D; Dorasamy A; Lewin S; Ndung'u T; Moosa MY; French M; Mlisana K; Coovadia Y
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):294-8. PubMed ID: 25277745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of diphenyl diselenide and ebselen alone and in combination with antifungal agents against Trichosporon asahii.
    Felli Kubiça T; Bedin Denardi L; Silva de Loreto É; Zeni G; Weiblen C; Oliveira V; Morais Santurio J; Hartz Alves S
    Mycoses; 2019 May; 62(5):428-433. PubMed ID: 30784136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
    Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
    Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis.
    Wirth F; de Azevedo MI; Pilla C; Aquino VR; Neto GW; Goldani LZ
    Med Mycol; 2018 Apr; 56(3):257-262. PubMed ID: 28992308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.
    Larsen RA; Bauer M; Thomas AM; Graybill JR
    Antimicrob Agents Chemother; 2004 Mar; 48(3):985-91. PubMed ID: 14982793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.
    Rodero L; Córdoba S; Cahn P; Hochenfellner F; Davel G; Canteros C; Kaufman S; Guelfand L
    J Antimicrob Chemother; 2000 Feb; 45(2):239-42. PubMed ID: 10660509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing.
    Soares BM; Santos DA; Kohler LM; da Costa César G; de Carvalho IR; dos Anjos Martins M; Cisalpino PS
    Rev Iberoam Micol; 2008 Dec; 25(4):242-5. PubMed ID: 19071894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility of Cryptococcus gattii clinical isolates.
    Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
    Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ebselen and diphenyl diselenide against fungal pathogens: A systematic review.
    Benelli JL; Poester VR; Munhoz LS; Melo AM; Trápaga MR; Stevens DA; Xavier MO
    Med Mycol; 2021 May; 59(5):409-421. PubMed ID: 33421963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
    Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.